Cemiplimab Clinical Trials

67 actively recruiting trials across 27 locations

Also known as: 1801342-60-8, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal REGN2810 Heavy Chain), Cemiplimab RWLC, Cemiplimab-rwlc, Disulfide with Human Monoclonal REGN2810 kappa-chain, Immunoglobulin G4, LIBTAYO, LIBTAYO®, Libtavo, Libtayo, Libtayo, REGN2810, Libtayo®, REGN 2810, REGN-2810, REGN2810, REGN2810 (PD1)_cemiplimab_LIBTAYO, REGN2810, LIBTAYO, SAR439684- Libtayo, cemiplimab-rwlc, libtayo

Filter by location:

Other13 trials

A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy

Phase 3

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

Phase 3

A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab

Phase 1

Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer

Phase 2

An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe

Cemiplimab as Maintenance Treatment for Advanced Adrenocortical Cancer

Phase 2

ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer

Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients

Phase 2

Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC

Phase 2

Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab.

PALACE: Cemiplimab Trial According to ctDNA Levels

Phase 2

Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy

Phase 2

THIO Sequenced With Cemiplimab in Advanced NSCLC

Phase 2

New York, New York5 trials

Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

Columbia University Irving Medical Center

Phase 2

Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)

Columbia University Irving Medical Center

Phase 2

Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)

Columbia University Irving Medical Center/ New York Presbyterian Hospital

Phase 2

Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC

Icahn School of Medicine at Mount Sinai

Phase 1/2

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

Weill Cornell Medicine

Phase 2

Birmingham, Alabama4 trials

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

University of Alabama at Birmingham

Phase 2

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

The University of Alabama at Birmingham

Phase 2

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

University of Alabama_6th Ave

Phase 1/2

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

University of Alabama at Birmingham Cancer Center

Phase 3

Los Angeles, California4 trials

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

California Research Institute

Phase 1

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

USC Norris Comprehensive Cancer Center

Phase 1/2

A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

Valkyrie Clinical Trials

Phase 1/2

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

The Angeles Clinic and Research Institute

Phase 2

Houston, Texas4 trials

A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

The University of Texas M. D. Anderson Cancer Center

Phase 1

Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC).

MD Anderson Cancer Center

Phase 2

Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors

Md Anderson Cancer Center

Phase 2

Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

MD Anderson Cancer Center

Phase 2

Phoenix, Arizona3 trials

Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

St. Joseph's Hospital and Medical Center

Phase 3

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Mayo Clinical

Phase 2

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

Medical Dermatology Specialists

Phase 3

Duarte, California3 trials

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

Site-113

Phase 1/2

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

City of Hope Comprehensive Cancer Center

Phase 1/2

Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer

City of Hope Medical Center

Phase 2

Baltimore, Maryland3 trials

Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer

Johns Hopkins SKCCC

Phase 2

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

JHU Sidney Kimmel Comprehensive Cancer Center LAO

Phase 2

Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca

Johns Hopkins University

Phase 2

Boston, Massachusetts3 trials

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

Massachusetts General Hospital Cancer Center

Phase 1/2

A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

Massachusetts General Hospital

Phase 1

XL092 and Cemiplimab in BRAF WT Thyroid Cancer

Dana Farber/Harvard Cancer Center

Phase 1

Gilbert, Arizona2 trials

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

Banner MD Anderson Cancer Center

Phase 1/2

The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer

Banner - MD Anderson Cancer

Phase 2

Scottsdale, Arizona2 trials

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Mayo Clinic in Arizona

Phase 1

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Mayo Clinic in Arizona

Phase 1

La Jolla, California2 trials

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Scripps Clinic Torrey Pines

Phase 1

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

UC San Diego Moores Cancer Center

Phase 2

Atlanta, Georgia2 trials

Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer

Emory University/Winship Cancer Institute

Phase 1

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

Emory University Hospital Midtown

Phase 2

Basking Ridge, New Jersey2 trials

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 1

A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activites)

Phase 2

Nashville, Tennessee2 trials

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Vanderbilt-Ingram Cancer Center

Phase 2

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Vanderbilt University/Ingram Cancer Center

Phase 1/2

Daphne, Alabama1 trial

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis

Phase 2/3

Chandler, Arizona1 trial

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

Ironwood Cancer & Research Centers

Phase 3

Orange, California1 trial

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

University of California Irvine

Phase 2

Palo Alto, California1 trial

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer

Stanford University Medical Center - Blake Wilbur Drive

Phase 1/2

Sacramento, California1 trial

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

Sutter Medical Center Sacramento

Phase 2

Tampa, Florida1 trial

Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC

Moffitt Cancer Center

Phase 2

Lexington, Kentucky1 trial

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

University of Kentucky Chandler Medical Center

Phase 1

Bethesda, Maryland1 trial

Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

National Cancer Institute

Phase 1

Rochester, Minnesota1 trial

Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer

Mayo Clinic in Rochester

Phase 2

The Bronx, New York1 trial

Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer

Montefiore Einstein Comprehensive Cancer Center (MECCC)

Phase 2

Columbus, Ohio1 trial

Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma

Ohio State University Comprehensive Cancer Center

Phase 2

Austin, Texas1 trial

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

NEXT Austin

Phase 1/2

Madison, Wisconsin1 trial

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

University of Wisconsin Carbone Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.